Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average […]
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) dropped 4.5% during mid-day trading on Monday . The company traded as low as $19.05 and last traded at $19.05. Approximately 8,331 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 539,488 shares. The stock had previously closed at $19.95. […]
Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its price target cut by Morgan Stanley from $37.00 to $24.00 in a research note released on Monday morning, Benzinga reports. They currently have an equal weight rating on the stock. KYMR has been the topic of a number of other reports. Credit Suisse Group lifted their price […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares gapped up prior to trading on Tuesday after an insider bought additional shares in the company. The stock had previously closed at $14.40, but opened at $15.30. Kymera Therapeutics shares last traded at $15.59, with a volume of 99,077 shares traded. Specifically, Director Bvf Partners L. […]